Published in Biotech Law Weekly, July 7th, 2006
The lab facility is in compliance with E.U. Good Manufacturing Practices (EU-GMP). This new lab is an advanced research facility that also has GMP cell production capabilities to support research related to Bioheart's adult muscle stem cell technology. Bioheart has developed MyoCell, a cell therapy that involves extracting and culturing cells from a patient's own thigh muscle.
These cells are inserted back into the patient's damaged heart region via the MyoCath, a minimally-invasive injection-catheter system. The research at the lab could lead...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.